First, this is a preliminary indication that DAPA could prevent cardiac dysfunctions and decrease biomarkers of cardiotoxicity in preclinical models of short-term-induced cardiomyopathies; however, a detailed mechanistic study of DAPA-related cardioprotection should be carried out, through the use of selective inhibitors of intracellular pathways potentially involved in beneficial properties of DAPA (i.e., through the use of NLRP-3 and MyD-88 selective inhibitors). The gene discussed is NLRP3; the disease is cardiomyopathy.